SCHEMBL16896993

SCHEMBL16896993

NC(=NO)c1ccnc(NS(=O)(=O)c2ccccc2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.46
KDM4E B2RXH2 3/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
HTT P42858 1/20 0.46
AURKA O14965 1/20 0.46
AURKB Q96GD4 1/20 0.46
BRD4 O60885 4/20 0.45
SLC40A1 Q9NP59 1/20 0.44
ALDH1A1 P00352 1/20 0.44
KAT6A Q92794 1/20 0.43
ALKBH2 Q6NS38 1/20 0.43
ALKBH5 Q6P6C2 1/20 0.43
FTO Q9C0B1 1/20 0.43
POLB P06746 1/20 0.42
F2 P00734 1/20 0.41
F10 P00742 1/20 0.41
FURIN P09958 1/20 0.41
SLC7A11 Q9UPY5 1/20 0.41
BRD3 Q15059 1/20 0.41
CREBBP Q92793 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13633459 0.87 KDM4E (0.50) LMNAKDM4ESMN1; SMN2HTTBRD4
SCHEMBL13633502 0.87 KDM4E (0.50) LMNAKDM4ESMN1; SMN2HTTBRD4
SCHEMBL16897016 0.84 TMPRSS6 (0.54) LMNAKDM4ESMN1; SMN2HTTSLC40A1
Hydrochloric Acid SCHEMBL16897057 0.83 TMPRSS6 (0.55) LMNAKDM4ESMN1; SMN2HTTSLC40A1
SCHEMBL13633521 0.80 CA12 (0.52) LMNAKDM4ESMN1; SMN2HTTALDH1A1
SCHEMBL16896992 0.77 KDM4E (0.50) LMNAKDM4ESMN1; SMN2HTTBRD4
SCHEMBL3457189 0.75 NR3C2 (0.41) ALDH1A1
SCHEMBL3457187 0.75 NR3C2 (0.41) ALDH1A1
SCHEMBL24554275 0.73 KDM4E (0.77) LMNAKDM4ESMN1; SMN2HTTALDH1A1
SCHEMBL29967291 0.73 KDM4E (0.77) LMNAKDM4ESMN1; SMN2HTTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3129372-B1 AZAQUINAZOLINE INHIBITORS OF ATYPICAL PROTEIN KINASE C CANCER RESEARCH TECH LTD (GB) 2020-12-16 EP disclosed
EP-2900666-B1 AZAQUINAZOLINE INHIBITORS OF ATYPICAL PROTEIN KINASE C CANCER RESEARCH TECH LTD (GB) 2020-11-04 EP disclosed
US-10414763-B2 Azaquinazoline inhibitors of atypical protein kinase C CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2019-09-17 US disclosed
CN-106470993-B The azepine quinazoline inhibitor of Atypical protein kinase C 癌症研究科技有限公司 2019-08-27 CN disclosed
CN-106470993-A The azepine quinazoline inhibitor of Atypical protein kinase C 癌症研究科技有限公司 2017-03-01 CN disclosed
EP-3129372-A1 AZAQUINAZOLINE INHIBITORS OF ATYPICAL PROTEIN KINASE C Cancer Research Technology Limited (GB) 2017-02-15 EP disclosed
WO-2015148597-A1 AZAQUINAZOLINE INHIBITORS OF ATYPICAL PROTEIN KINASE C IGNYTA, INC. (US) 2015-10-01 WO disclosed
US-20150274720-A1 Azaquinazoline Inhibitors Of Atypical Protein Kinase C WINDTREE THERAPEUTICS, INC. 2015-10-01 US disclosed
WO-2014052699-A9 AZAQUINAZOLINE INHIBITORS OF ATYPICAL PROTEIN KINASE C IGNYTA, INC. (US) 2015-07-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10414763-B2 Azaquinazoline inhibitors of atypical protein kinase C PRKCQ, PRKCA, PRKCZ LMNA 2699/4885KDM4E 1233/4885SMN1; SMN2 4371/4885
US-20150274720-A1 Azaquinazoline Inhibitors Of Atypical Protein Kinase C PRKCQ, PRKCA, PRKCZ LMNA 2699/4885KDM4E 1233/4885SMN1; SMN2 4371/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.